(Re)Formulating Rotigotine: a Potential Molecule With Unmet Needs
Therapeutic Delivery · 2022
DOI: 10.4155/tde-2022-0046 ↗Kurz gefasst
Editorial in der Zeitschrift Therapeutic Delivery, 2022. Verfasst von Paramita Saha und 2 weiteren Autor:innen. Beteiligte Einrichtung: Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science, Pilani, Rajasthan, 333031, India. Hauptthemen laut MEDLINE: Dopamine Agonists, Parkinson Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Rotigotine (RTG), a non-ergoline D3/D2/D1 dopamine receptor agonist, is indicated for Parkinson's disease (PD) and restless leg syndrome (RLS) [1]. It also has an affinity toward serotonin (5-HT1A,...
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science, Pilani, Rajasthan, 333031, India.
ORCID-Profile: Murali Monohar Pandey
Zitieren
APA
Saha, P., Chitkara, D., & Pandey, M. M. (2022). (Re)Formulating Rotigotine: a Potential Molecule With Unmet Needs. Therapeutic Delivery. https://doi.org/10.4155/tde-2022-0046
Vancouver
Saha P, Chitkara D, Pandey MM. (Re)Formulating Rotigotine: a Potential Molecule With Unmet Needs. Therapeutic Delivery. 2022. doi:10.4155/tde-2022-0046
BibTeX
@article{Saha2022,
author = {Saha, Paramita and Chitkara, Deepak and Pandey, Murali Monohar},
title = {(Re)Formulating Rotigotine: a Potential Molecule With Unmet Needs},
journal = {Therapeutic Delivery},
year = {2022},
doi = {10.4155/tde-2022-0046}
}
EUVIMED